Please login to the form below

Not currently logged in

GSK sells penicillin facility to Dr Reddy’s

GlaxoSmithKline has sold its US oral penicillin facility and product portfolio to India’s Dr Reddy's Laboratories for an undisclosed sum

GlaxoSmithKline (GSK) has sold its US oral penicillin facility and product portfolio to India's Dr Reddy's Laboratories for an undisclosed sum. This sale is expected to close in the first half of 2011. 

The deal gives Dr Reddy's ownership of a penicillin manufacturing site in Bristol, Tennessee, as well as US rights for the antibiotics Augmentin and Amoxil, with GSK retaining rights outside the US. Both drugs are off-patent in the US and are available from other companies as lower-cost generics.

Amoxil (amoxicillin) is used to treat bacterial infections including pneumonia; bronchitis; gonorrhea; and infections of the ears, nose, throat, urinary tract, and skin. Augmentin combines amoxicillin with clavulanate potassium, which is used to overcome resistance in certain kinds of bacteria.

Divesting the assets "will allow GSK to focus resources on our newer portfolio of differentiated products," said Jean-Paul Reynaud, senior vice president, antibiotics and emerging markets supply at GSK. Just last month, the company signed a deal with Japanese drugmaker Shionogi & Co. to develop new antibiotics to fight multidrug-resistant bacteria.

For Dr Reddy's, which has a focus on generics, acquiring the assets "allows us to enter the United States penicillin-containing antibacterial market segment…in line with our strategy to significantly scale up our generics business in North America while providing an opportunity to explore additional synergy with our other businesses," said Abhijit Mukherjee, who leads the company's global generics business.

25th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...